Видео ютуба по тегу Charles Fuchs

Charles Fuchs, MD: Mutations in Colorectal Cancer
Charles Fuchs, MD: Mutations in Colorectal Cancer
Charles Fuchs, MD: Bevacizumab Plus Chemotherapy
Charles Fuchs, MD: Bevacizumab Plus Chemotherapy
Cancer Dialogue Ep.1: Charles Fuchs and Luis Paz-Ares at ESMO 2024
Cancer Dialogue Ep.1: Charles Fuchs and Luis Paz-Ares at ESMO 2024
Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies
Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies
Charles Fuchs, MD: Chemotherapy Side Effects
Charles Fuchs, MD: Chemotherapy Side Effects
Charles Fuchs, MD: Treatment Toxicities and Quality of Life
Charles Fuchs, MD: Treatment Toxicities and Quality of Life
FDA Approves New Stomach Cancer drug/Dr. Charles Fuchs, Yale Cancer Center
FDA Approves New Stomach Cancer drug/Dr. Charles Fuchs, Yale Cancer Center
Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer
Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer
Charles Fuchs, MD: Experience With Patients on Bevacizumab Plus Chemotherapy
Charles Fuchs, MD: Experience With Patients on Bevacizumab Plus Chemotherapy
Charles Fuchs, MD: Clinical Importance of RAS Mutations
Charles Fuchs, MD: Clinical Importance of RAS Mutations
Yale Cancer Center- Eating nuts may aid colon cancer survival
Yale Cancer Center- Eating nuts may aid colon cancer survival
Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC
Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC
Charles Fuchs, MD: Strategies to Increase RAS Testing
Charles Fuchs, MD: Strategies to Increase RAS Testing
Optimizing Frontline Chemotherapy in Metastatic Colorectal Cancer
Optimizing Frontline Chemotherapy in Metastatic Colorectal Cancer
Charles Fuchs hits the Golf Course!!
Charles Fuchs hits the Golf Course!!
Charles Fuchs, MD: Cost Issues With CT Regimens and Bevacizumab
Charles Fuchs, MD: Cost Issues With CT Regimens and Bevacizumab
Charles Fuchs, MD: First Line Treatments in Unresectable Colon Cancer
Charles Fuchs, MD: First Line Treatments in Unresectable Colon Cancer
Charles Fuchs, MD: Impeding RAS Mutation Testing
Charles Fuchs, MD: Impeding RAS Mutation Testing
CALGB/SWOG 80702: celecoxib and FOLFOX in stage III colon cancer
CALGB/SWOG 80702: celecoxib and FOLFOX in stage III colon cancer